About this courseSkip About this course
This course focuses on early-stage biotechnology companies, with particular emphasis on understanding the underlying science, technology, and disease targets—together with the application of novel business structures and financing methods—to facilitate drug discovery, clinical development, and greater patient access to new therapies.
Current research is enhancing our understanding of the genetic, molecular, and cellular bases of many human diseases, and is leading to many new types of biotherapeutics that we will cover in this course, including recombinant therapeutic proteins; monoclonal antibodies and antibody drug conjugates; cancer immunotherapies, replacement cells and genetically engineered cells; and nucleic acid and gene therapies. Translating these discoveries into drugs and diagnostics increasingly requires the establishment of for-profit companies, but funding for early-stage development of novel therapies is becoming scarcer, especially for therapeutics for “rare” diseases that affect small populations. The dearth of funding for early-stage biotherapeutics companies in the so-called “Valley of Death” can be attributed to several factors, but a common thread is increasing financial risks in the biopharma industry and greater uncertainty surrounding the scientific, medical, economic, political, and academic environments within the biomedical ecosystem. Increasing risk and uncertainty inevitably leads to an outflow of capital as investors and other stakeholders seek more attractive opportunities in other industries.
By applying financial techniques such as portfolio theory, securitization, and derivative securities to biomedical contexts, more efficient business and funding structures can be developed to reduce financial risks, lower the cost of capital, and bring more life-saving therapies to patients faster. Thus this course will also cover basic financial analysis for the life-sciences professional; the historical financial risks and returns of the biotech and pharmaceutical industries; the evaluation of the science and business potential as well as the mechanics of financing biotech startups; capital budgeting for biopharmaceutical companies; and applications of financial engineering in drug royalty investment companies, biomedical megafunds, drug approval swaps, and life sciences investment banking.
What you'll learnSkip What you'll learn
- Basic financial analysis for the life-sciences professional
- The historical financial risks and returns of the biopharma industry
- Capital budgeting for pharmaceutical companies
- Drug development and clinical trials
- The mechanics of biotech startup financing
- Biomedical megafunds and drug royalty investment companies
- Healthcare analytics and machine learning
- Pricing, value, and ethics
* Week 0:** Intro to the Science of Biotech and Healthcare Finance
- Week 1: Therapeutic Recombinant Proteins; Present Value
* Week 2:** AAV Vectors & In Vivo Gene Therapy; Capital Budgeting
* Week 3:** Ex Vivo Gene Therapy; Stocks and Bonds
* Week 4:** Nucleic Acid Therapies; The CAPM & Diversification
* Week 5:** Gene Editing; Options
* Week 6:** Clinical Trials
- Week 7: Antibody Generation; Venture Capital & New Business Models
* Week 8:** Monoclonal Antibodies; Securitization
* Week 9:** Cancer Immunotherapeutic; Healthcare Analytics
* Week 10:** New Cell Therapies; Pricing, Value & Ethics
Meet your instructors
Pursue a Verified Certificate to highlight the knowledge and skills you gain$49 USD
Official and Verified
Receive an instructor-signed certificate with the institution's logo to verify your achievement and increase your job prospects
Add the certificate to your CV or resume, or post it directly on LinkedIn
Give yourself an additional incentive to complete the course
Support our Mission
EdX, a non-profit, relies on verified certificates to help fund free education for everyone globally
Who can take this course?
Unfortunately, learners from one or more of the following countries or regions will not be able to register for this course: Iran, Cuba and the Crimea region of Ukraine. While edX has sought licenses from the U.S. Office of Foreign Assets Control (OFAC) to offer our courses to learners in these countries and regions, the licenses we have received are not broad enough to allow us to offer this course in all locations. EdX truly regrets that U.S. sanctions prevent us from offering all of our courses to everyone, no matter where they live.